Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) Research & Development (2020 - 2025)

Historic Research & Development for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $29.9 million.

  • Cellebrite DI's Research & Development rose 1666.47% to $29.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $113.9 million, marking a year-over-year increase of 1571.1%. This contributed to the annual value of $113.9 million for FY2025, which is 1571.1% up from last year.
  • Per Cellebrite DI's latest filing, its Research & Development stood at $29.9 million for Q4 2025, which was up 1666.47% from $28.1 million recorded in Q3 2025.
  • Cellebrite DI's Research & Development's 5-year high stood at $29.9 million during Q4 2025, with a 5-year trough of $14.9 million in Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $21.4 million (2022), whereas its average is $22.1 million.
  • In the last 5 years, Cellebrite DI's Research & Development skyrocketed by 3170.39% in 2022 and then tumbled by 547.26% in 2023.
  • Cellebrite DI's Research & Development (Quarter) stood at $18.8 million in 2021, then increased by 4.78% to $19.7 million in 2022, then rose by 10.22% to $21.8 million in 2023, then increased by 17.69% to $25.6 million in 2024, then increased by 16.66% to $29.9 million in 2025.
  • Its Research & Development was $29.9 million in Q4 2025, compared to $28.1 million in Q3 2025 and $28.6 million in Q2 2025.